MUNICH – With more than three years of follow-up, median progression-free survival (PFS) has yet to be reached in the treatment arm of the SOLO-1 study. Patients receiving placebo had a median progression-free survival (PFS) of 13.8 months, making for a hazard ratio of 0.3 and data that seem likely to turn Lynparza (olaparib, Astrazeneca plc) into the front-line standard of care for women with BRCA mutations.
MUNICH – Lynparza's front-line effects in the treatment of ovarian cancer were the most eye-popping data on poly-(ADP-ribose) polymerase (PARP) inhibitors presented at the European Society of Medical Oncology (ESMO) 2018 Congress.
Researchers at the University of California at San Diego have identified a target for selectively inducing programmed cell death in latently HIV-infected T cells, opening up a new strategy for eliminating the reservoir of nondividing infected host cells that are currently the biggest barrier to an HIV cure.
By sequencing the gut microbiome of individuals with bloodstream infections, researchers have challenged conventional medical wisdom about the source of those infections. The sequencing tool they developed, Strainsifter, may be used to inform antibiotic treatment for such infections in the future.
A team from the Mount Sinai School of Medicine and Columbia University Medical Center has shown aberrant splicing was a widespread feature in Alzheimer's disease (AD), and that alternatively spliced variants were present in several AD risk genes.
Researchers from the University of British Columbia have shown that in a mouse model, silencing mutant Huntingtin protein with antisense oligonucleotides was not just effective against the motor problems that are the most salient part of Huntington's chorea (HD), but could also prevent and even reverse the equally troubling cognitive and psychiatric symptoms that are part of the disease.
Researchers from Korea National University have identified the enzyme acid sphingomyelinase (ASM) as a contributor to increased blood-brain barrier (BBB) permeability, resulting in neurocognitive dysfunction, during aging.
